Insider Monkey
Is Edwards Lifesciences Corporation (EW) A Good Stock To Buy Now?
📈
AI Sentiment
Highly Positive
8/10
- Home
- EW
as of 03-23-2026 2:36pm EST
$82.40
$0.14
-0.17%
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 50.2B | IPO Year: | 1999 |
| Target Price: | $96.47 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.83 | EPS Growth: | -73.74 |
| 52 Week Low/High: | $65.94 - $87.89 | Next Earning Date: | 04-22-2026 |
| Revenue: | $6,067,600,000 | Revenue Growth: | 11.55% |
| Revenue Growth (this year): | 13.39% | Revenue Growth (next year): | 9.78% |
| P/E Ratio: | 45.10 | Index: | |
| Free Cash Flow: | 1.3B | FCF Growth: | +360.50% |
AI-Powered EW Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 75.90%
75.90%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
Ullem Scott B.
Sell
CVP, Chief Financial Officer
EW Mar 11, 2026
Avg Cost/Share
$84.83
Shares
13,000
Total Value
$1,103,895.79
Owned After
47,600
Lippis Daniel J.
Sell
CVP, TAVR
EW Mar 11, 2026
Avg Cost/Share
$85.38
Shares
1,019
Total Value
$87,004.46
Owned After
33,933.91
SEC Form 4
BOBO DONALD E JR
Sell
CVP,Strategy/Corp Development
EW Mar 2, 2026
Avg Cost/Share
$85.93
Shares
11,340
Total Value
$974,430.32
Owned After
21,266.253
SEC Form 4
BOBO DONALD E JR
Sell
CVP,Strategy/Corp Development
EW Feb 25, 2026
Avg Cost/Share
$83.84
Shares
24,000
Total Value
$2,012,076.00
Owned After
21,266.253
SEC Form 4
Lippis Daniel J.
Sell
CVP, TAVR
EW Jan 9, 2026
Avg Cost/Share
$85.70
Shares
1,019
Total Value
$87,332.07
Owned After
33,933.91
SEC Form 4
BOBO DONALD E JR
Sell
CVP,Strategy/Corp Development
EW Jan 6, 2026
Avg Cost/Share
$85.30
Shares
11,340
Total Value
$971,429.16
Owned After
21,266.253
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Mar 11, 2026 | Sell | $84.83 | 13,000 | $1,103,895.79 | 47,600 | |
| Lippis Daniel J. | EW | CVP, TAVR | Mar 11, 2026 | Sell | $85.38 | 1,019 | $87,004.46 | 33,933.91 | |
| BOBO DONALD E JR | EW | CVP,Strategy/Corp Development | Mar 2, 2026 | Sell | $85.93 | 11,340 | $974,430.32 | 21,266.253 | |
| BOBO DONALD E JR | EW | CVP,Strategy/Corp Development | Feb 25, 2026 | Sell | $83.84 | 24,000 | $2,012,076.00 | 21,266.253 | |
| Lippis Daniel J. | EW | CVP, TAVR | Jan 9, 2026 | Sell | $85.70 | 1,019 | $87,332.07 | 33,933.91 | |
| BOBO DONALD E JR | EW | CVP,Strategy/Corp Development | Jan 6, 2026 | Sell | $85.30 | 11,340 | $971,429.16 | 21,266.253 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 10, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 10, 2026 · 100% conf.
AI Prediction SELL
1D
-6.98%
$71.67
Act: +2.96%
5D
-7.87%
$70.99
Act: +2.50%
20D
-3.17%
$74.60
Act: +10.14%
Price: $77.05 Prob +5D: 0% AUC: 1.000
0001099800-26-000006
ew-202602100001099800false00010998002026-02-102026-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 10, 2026
EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commission file number) (IRS Employer Identification No.)
One Edwards Way Irvine, California 92614 (Address of principal executive offices and zip code)
(949) 250-2500 (Registrant's telephone number, including area code)
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $1.00 per shareEWNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 10, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the fourth quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference.
The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1Press release, dated February 10, 2026, reporting Edwards’ financial results for the fourth quarter of 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 10, 2026
EDWARDS LIFESCIENCES CORPORATION
By:/s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer
3
Exhibit Index
Exhibit Number Description 99.1 Press release, dated February 10, 2026, reporting Edwards’ financial results for the fourth quarter of 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
4
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 30, 2025
0001099800-25-000059
ew-202510300001099800false00010998002025-10-302025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 30, 2025
EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commission file number) (IRS Employer Identification No.)
One Edwards Way Irvine, California 92614 (Address of principal executive offices and zip code)
(949) 250-2500 (Registrant's telephone number, including area code)
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $1.00 per shareEWNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On October 30, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference.
The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1Press release, dated October 30, 2025, reporting Edwards’ financial results for the third quarter of 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 30, 2025
EDWARDS LIFESCIENCES CORPORATION
By:/s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer
3
Exhibit Index
Exhibit Number Description 99.1 Press release, dated October 30, 2025, reporting Edwards’ financial results for the third quarter of 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
4
2025 Q2 Q2 2025 Earnings
8-K Jul 24, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 24, 2025
0001099800-25-000037
ew-202507240001099800false00010998002025-07-242025-07-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 24, 2025
EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 1-15525 36-4316614 (State or other jurisdiction of incorporation) (Commission file number) (IRS Employer Identification No.)
One Edwards Way Irvine, California 92614 (Address of principal executive offices and zip code)
(949) 250-2500 (Registrant's telephone number, including area code)
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $1.00 per shareEWNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 24, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference.
The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1Press release, dated July 24, 2025, reporting Edwards’ financial results for the second quarter of 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 24, 2025
EDWARDS LIFESCIENCES CORPORATION
By:/s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer
3
Exhibit Index
Exhibit Number Description 99.1 Press release, dated July 24, 2025, reporting Edwards’ financial results for the second quarter of 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
4
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
Simply Wall St.
Edwards Lifesciences (EW) Valuation Check After Recent Share Price Momentum
📊
AI Sentiment
Positive
7/10
Compare EW vs Leading Stocks
See how EW stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.